Moberg Pharma AB

MOB

SE0020353928

Pharmaceuticals

Market Closed - Nasdaq Stockholm Other stock markets 11:29:49 2024-04-29 am EDT			5-day change	1st Jan Change
34 ^SEK	+2.53%		+13.64%	+123.68%

Apr. 08	Moberg Pharma AB Submits Application to Include an Additional Terbinafine Supplier	CI
Feb. 26	Certain Ordinary Shares of Moberg Pharma AB are subject to a Lock-Up Agreement Ending on 26-FEB-2024.	CI

Moberg Pharma AB and Taisho Pharmaceutical Co., Ltd Terminate License Agreement for MOB-015 in Japan

March 09, 2023 at 02:00 am EST

Moberg Pharma AB announced that Taisho Pharmaceutical Co., Ltd. and Moberg Pharma terminate the license agreement for development, registration and commercialization of MOB-015 in Japan. Moberg Pharma regains full rights to the product in Japan and retains milestone revenues paid by Taisho. Taisho has conducted an extensive review on its R&D pipeline and decided to stop the development on MOB-015 due to strategic reasons.

Therefore, Moberg Pharma now regains the full rights for MOB-015 in Japan.

Latest news about Moberg Pharma AB

Moberg Pharma AB Submits Application to Include an Additional Terbinafine Supplier	Apr. 08	CI
Certain Ordinary Shares of Moberg Pharma AB are subject to a Lock-Up Agreement Ending on 26-FEB-2024.	Feb. 25	CI
Moberg Pharma AB Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 13	CI
Moberg Pharma AB Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 13	CI
Moberg Pharma AB Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 07	CI
Moberg Pharma Announces Leadership Changes	Nov. 07	CI
Moberg Pharma AB Appoints Nomination Committee	23-10-17	CI
Moberg Pharma Completes Patient Recruitment for North American Trial of Nail Fungus Treatment	23-10-06	MT
Moberg Pharma Completes Enrollment to the Phase 3 Study for Mob-015 in North America	23-10-06	CI
Moberg Pharma to Issue New Units as Guarantors' Commission; Shares Falls 11%	23-09-08	MT
Moberg Pharma Raises SEK100 Million in Oversubscribed Rights Issue; Shares Surge 22%	23-09-01	MT
Moberg Pharma to Launch SEK100 Million Rights Offering	23-08-07	MT
Moberg Pharma Surges 39% With Swedish Approval for Fungal Nail Infection Treatment	23-08-04	MT
Moberg Pharma AB Announces National Approval for MOB-015 in Sweden	23-08-04	CI
Moberg Pharma AB Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-03	CI
Moberg Pharma AB Announces That Mob-015 has Received National Approval in Ireland for the Treatment of Mild to Moderate Fungal Infections of the Nails in Adults	23-07-31	CI
Cipher Pharmaceuticals Partner, Moberg Pharma, Announces Approval for MOB-015 in the European Union	23-07-05	MT
Cipher Pharmaceuticals Brief: Partner, Moberg Pharma Announcing Approval for MOB-015 in the European Union	23-07-05	MT
Moberg Pharma AB Announces Approval for Mob-015 in the European Union	23-07-05	CI
Moberg Pharma's Antifungal Medicine Backed for Approval in 13 EU Nations; Shares Tank 39%	23-06-28	MT
Moberg Pharma AB Recommends for Approval in EU	23-06-28	CI
Moberg Pharma AB Elects Håkan Wallin to the Board Members	23-05-16	CI
Moberg Pharma AB Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-09	CI
Moberg Pharma AB and Taisho Pharmaceutical Co., Ltd Terminate License Agreement for MOB-015 in Japan	23-03-09	CI
Moberg Pharma AB Reports Earnings Results for the Full Year Ended December 31, 2022	23-02-07	CI

Chart Moberg Pharma AB

Duration

Period

More charts

Company Profile

Moberg Pharma AB is a Sweden-based pharmaceutical company. Its product portfolio includes products for the treatment of skin diseases and pain, such as Emtrix/Nalox, for the treatment of nails damaged by fungus or psoriasis; Kerasal, for dry and damaged feet, and Kaprolac, a range of products for several types of skin and scalp problems. Additionally, the Company has two projects in phase II of development, namely MOB-15, for the treatment of nail fungus, and Limtop, for the treatment of actinic keratosis, basalioma and genital warts. The Company collaborates with Meda AB, Menarini Group, Perrigo Company, OzHealth Pharma and Zelmic AB, among others. It is active in more than 35 countries, and operates, among others, through Alterna LLC. It also owns three Over-The-Counter (OTC) brands in the United States.

Sector

Pharmaceuticals

Calendar

2024-05-07 - Q1 2024 Earnings Release

More about the company

Sector Other Pharmaceuticals

	1st Jan change	Capi.
MOBERG PHARMA AB	+123.68%	84.57M
ELI LILLY AND COMPANY	+25.74%	661B
NOVO NORDISK A/S	+26.74%	566B
JOHNSON & JOHNSON	-6.75%	352B
MERCK & CO., INC.	+19.47%	332B
ABBVIE INC.	+3.28%	283B
ASTRAZENECA PLC	+13.43%	231B
NOVARTIS AG	+4.71%	200B
ROCHE HOLDING AG	-9.53%	195B
AMGEN INC.	-4.23%	145B

Other Pharmaceuticals

Moberg Pharma AB

Equities

MOB

SE0020353928

Pharmaceuticals

Moberg Pharma AB and Taisho Pharmaceutical Co., Ltd Terminate License Agreement for MOB-015 in Japan

Latest news about Moberg Pharma AB

Chart Moberg Pharma AB

Company Profile

Income Statement Evolution

EPS Revisions

Annual profits - Rate of surprise

Sector Other Pharmaceuticals